Toshifumi Tada serves as Chairperson of the board of directors since April 2025.
He is Vice President of Asia and Europe Business at Mitsubishi Tanabe Pharma Corporation (MTPC), NeuroDerm’s parent company. Before the current position, he has more than 25 years of experiences in the pharmaceutical industry and took on leadership positions in various countries such as Japan, US, Canada, Singapore and Indonesia at MTPC and its group companies.
He earned Master degree of Business Administration and holds Certified Management Accountant qualification.

Dr. Taguchi has been serving as a member of the board of directors since April 2020.

He started his career as a pharmaceutical scientist at the Pharmaceutical Research Department at Tanabe Seiyaku in 1994.

He has accumulated experience in designing oral drug formulations, manufacturing of investigational products, industrialization toward commercialization, and applications for approval; he has also worked on several products, including OTC products, which are still sold on the Japanese market.

He has been engaged in LCM strategy planning of existing drugs in the Global Product Strategy Department since 2009. Since 2013, he has been working on technology transfer processes for existing products at the Production Division and has outsourced many products and subsequently managed CMO.

He is currently the Vice President, Head of Supply Chain Management Department, Production Technology & Supply Chain Management Division, Mitsubishi Tanabe Pharma Corporation.

Dr. Taguchi received a master’s degree in pharmacy from Kobe Gakuin University and a Ph.D. in pharmacy from Osaka University.

Mr. Isshiki was appointed NeuroDerm’s CEO in December 2022, after serving as NeuroDerm’s Chief Administrative Officer since 2020. With over 28 years of international business experience in the pharmaceutical industry, he has overseen the growth of global pharmaceutical companies and directed long-term strategic plans.

At his previous capacity as CAO, Mr. Isshiki was in charge on directing the company’s finance, HR, legal advisory and IP activities. Prior to this, Mr. Isshiki had served as the Company’s VP Planning & Coordination and oversaw post-merger integration on-site. He played, and continues to play, an important role in facilitating mutual understanding between two different cultures – that of a fast-paced, Israel-based R&D powerhouse, and that of a Japanese multinational corporation.

Mr. Isshiki has held a variety of research and managerial roles with increasing responsibilities since joining Tanabe Seiyaku in 1994. He had previously served as Senior Manager of the Corporate Strategic Planning Department of the Mitsubishi Tanabe Pharma Corporation where he was responsible for establishing the company’s medium-term business plan and managing R&D projects.

Mr. Isshiki received his MSc in Enzymology from Tohoku University in Japan.

Junya Namba serves as a board of directors since May 2024.

He has extensive experiences in the global pharmaceutical industry, especially, he has been engaged in global business operations, corporate strategy & planning and corporate management fields. He took such leadership roles in various countries such as Japan, UK, Germany, Indonesia, Canada and USA. Currently, he takes an Executive Director position at Mitsubishi Tanabe Pharma America, one of the subsidiaries of Mitsubishi Tanabe Pharma Corporation.